Changes in minimum inhibitory concentration of levofloxacin for Escherichia coli strains isolated from urine samples in mainland China, 2004 to 2014  by Li, Yun et al.
+ MODEL
Journal of Microbiology, Immunology and Infection (2016) xx, 1e3Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.e- jmii .comBRIEF COMMUNICATIONChanges in minimum inhibitory
concentration of levofloxacin for
Escherichia coli strains isolated from urine
samples in mainland China, 2004 to 2014
Yun Li a, Bo Zheng a,*, Feng Xue a, Sai-Nan Zhu b, Yuan Lyu aa Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100034, China
b Department of Biostatistics, Peking University First Hospital, Beijing 100034, ChinaReceived 24 May 2016; received in revised form 30 May 2016; accepted 27 June 2016
Available online - - -KEYWORDS
Escherichia coli;
levofloxacin;
susceptibility;
urinary tract
infection* Corresponding author. Institute
Peking University First Hospital, Numb
District, 100034 Beijing, China.
E-mail address: doctorzhengbo@16
Please cite this article in press as: L
isolated from urine samples in mai
dx.doi.org/10.1016/j.jmii.2016.06.00
http://dx.doi.org/10.1016/j.jmii.2016
1684-1182/Copyright ª 2016, Taiwan S
BY-NC-ND license (http://creativecomAbstract Eschrichia coli urinary isolates were collected from 20 Chinese hospitals during five
1-year periods from 2004 to 2014. The susceptibility of E. coli to levofloxacin has remained sta-
ble during the past 11 years, and 90% of strains had minimum inhibitory concentrations of
32 mg/L. The urine-specific susceptibility breakpoints for levofloxacin should be reset based
on more relevant clinical studies and the current pharmacokinetic/pharmacodynamic consid-
erations in this field.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Urinary tract infections (UTIs) are the most frequently
occurring bacterial infections, both in the community and
in hospitals. Escherichia coli is the most commonly
encountered uropathogen. Several international guidelines
recommend levofloxacin as the drug of choice for empirical
treatment of UTIs, including catheter-associated UTIs.1,2of Clinical Pharmacology,
er 8, Xishiku Street, Xicheng
3.com (B. Zheng).
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ociety of Microbiology. Published
mons.org/licenses/by-nc-nd/4.0/However, the widespread use of levofloxacin for compli-
cated or catheter-associated UTIs might result in reduced
susceptibility of E. coli to levofloxacin.3
The aim of this study was to evaluate and compare the
susceptibility pattern of E. coli urinary isolates to levo-
floxacin in mainland China during five 1-year periods from
2004 to 2014.
Materials and methods
Isolates
Overall, a total of 1127 nonreplicate clinical E. coli urinary
isolates were collected from 20 widely dispersed tertiaryhibitory concentration of levofloxacin for Escherichia coli strains
rnal of Microbiology, Immunology and Infection (2016), http://
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+ MODELhospitals in China during five 1-year periods (October
2004eSeptember 2005, January 2007eDecember 2007, July
2009eJune 2010, July 2011eJune 2012, and July
2013eJune 2014). All isolates were sent to the Institute of
Clinical Pharmacology, Peking University First Hospital,
where they were stored at 80C until further analysis.
Antimicrobial susceptibility testing
Susceptibility to antimicrobial agents was determined using
the agar dilution method established by the Clinical and
Laboratory Standards Institute. Extended-spectrum beta-
lactamase (ESBL)-producing isolates were detected using
previously described methods.4 The control strain was
ATCC 25922. The breakpoint for resistance to levofloxacin
for E. coli was 8 mg/L, and sensitivity was defined as a
minimum inhibitory concentration (MIC) of 2 mg/L.4
Statistical analyses
Statistical tests were performed using SPSS for Windows,
version 14.0 (SPSS Inc., Chicago, IL, USA). Enumeration
data were expressed as percentages. Differences in sus-
ceptibility between the groups were compared using the
chi-square test or Fisher’s exact test. Differences were
considered statistically significant at a two-sided p value of
<0.05. The Bonferroni method was used to adjust the sig-
nificance levels (0.05/10 Z 0.005) in multiple comparisons
between any two levels of the susceptibility outcome.
Results and discussion
Less than 33% of the isolates were susceptible to levo-
floxacin, and more than 90% of strains had MICs of 32 mg/
L. The ESBL positivity rate was 41.7% during October
2004eSeptember 2005 and increased to 58.7% during
January 2007eDecember 2007, to 66.0% during JulyTable 1 Susceptibility of Escherichia coli to levofloxacin, 2004
Year All strains
No. ESBL
(%)
MIC50
(mg/L)
MIC90
(mg/L)
S (%) R (%) No.
October 2004e
September 2005
168 41.7 8 32 31.0 62.5 70
January 2007e
December 2007
271 58.7* 16 32 28.0 66.7 159
July 2009e
June 2010
262 66.0* 8 32 28.2 64.9 173
July 2011e
June 2012
207 60.9* 8 32 32.4 61.3 126
July 2013e
June 2014
219 69.4* 8 32 33.8 61.2 152
October 2004e
June 2014
1127 58.1 8 32 30.4 64.2 680
p <0.001 0.579
* Compared with October 2004eSeptember 2005, p  0.001.
ESBLZ extended-spectrum beta-lactamase; IZ intermediate; MICZ
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to 69.4% during July 2013eJune 2014 (p < 0.001). However,
the levofloxacin susceptibility rate (about 30%) remained
stable throughout the study period (p Z 0.579; Table 1).
Levofloxacin showed 13.2% to 23.7% activity against
ESBL-producing strains of E. coli with 37.8% to 56.7% ac-
tivity against non-ESBL-producing strains in different years
(MIC  2.0 mg/L). Non-ESBL-producing E. coli isolates
showed significantly higher levofloxacin susceptibility rates
than did ESBL-producing isolates. The MIC50 of levofloxacin
for ESBL-producing and non-ESBL-producing isolates was 16
and 4 mg/L, respectively. The MIC90 was 32 mg/L for all
isolates (Table 1).
Levofloxacin and cephalosporins have been widely used
in the management of UTIs in China for a long time. We
observed a decline in the susceptibility to cefuroxime,
cefotaxime, and cefepime from 2004 to 2012 in China,5 but
the susceptibility of E. coli to levofloxacin remained stable
at about 30%; this was lower than the susceptibility in the
United States (65.2%).6 The increased use of fluo-
roquinolones has resulted in the rapid emergence of
fluoroquinolone-resistant E. coli and other uropathogens,
raising concerns about whether fluoroquinolones should
remain the drugs of choice for UTIs.7 In a current consensus
review from the Asia Pacific region, fluoroquinolones (cip-
rofloxacin and levofloxacin) were not recommended as the
drugs of choice for the treatment of UTIs if the rate of
resistance of urinary E. coli isolates to fluoroquinolones
was greater than 20%.8 In our clinical practice, the symp-
toms of many patients with lower UTIs resolved in 7 days
after treatment with levofloxacin at 500 mg daily, but the
urine culture revealed levofloxacin-resistant E. coli. The
Clinical and Laboratory Standards Institute provided a
urine-specific breakpoint for Enterobacteriaceae for some
fluoroquinolones (lomefloxacin, ofloxacin, and nor-
floxacin), but not for levofloxacin. Although most clinical
microbiology laboratories determine the susceptibilities of
urinary isolates of Enterobacteriaceae to levofloxacin bye2014.
ESBL positive ESBL negative
MIC50
(mg/L)
MIC90
(mg/L)
S (%) R (%) No. MIC50
(mg/L)
MIC90
(mg/L)
S (%) R (%)
16 64 21.4 71.5 98 8 32 37.8 56.1
16 32 13.2 83.0 112 4 32 49.1 43.8
16 32 17.3 76.3 89 4 32 49.4 42.7
16 32 19.8 76.2 81 1 32 51.9 38.3
8 64 23.7 71.7 67 1 16 56.7 37.3
16 32 18.7 76.3 447 4 32 48.3 44.3
0.177 0.150
minimum inhibitory concentration; RZ resistant; SZ sensitive.
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mean that levofloxacin is not a suitable treatment for UTIs
caused by pathogens with “in vitro resistance” to the
agent.8 Previous studies have clearly demonstrated that
the mean peak urinary concentration of levofloxacin
(0.0e1.5 hours) was 347 mg/L at a dose of 500 mg. Levo-
floxacin exhibited early (0.0- to 1.5-hour period) bacteri-
cidal activity of virtually all participants against study
isolates with MICs of 32 mg/L.9
The urine-specific susceptibility breakpoints for levo-
floxacin should be reset based on more relevant clinical
studies, especially in regions with a high prevalence of UTIs
caused by multidrug-resistant uropathogens. This is espe-
cially prudent given the current pharmacokinetic/pharma-
codynamic considerations in this field. Fluoroquinolone
resistance within society should also be meticulously
investigated.7
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